肿瘤综合治疗电子杂志2026，Vol.12Issue(1)：14-21,8.DOI:10.12151/JMCM.2026.01-03
2025年度神经内分泌肿瘤药物治疗研究进展
Annual progress in the treatment of neuroendocrine neoplasms in 2025
陈洛海 1陈洁1
作者信息
- 1. 复旦大学附属肿瘤医院 神经内分泌肿瘤中心 复旦大学上海医学院 肿瘤学系,上海 200032
- 折叠
摘要
Abstract
The incidence of neuroendocrine neoplasms(NENs)continues to rise.Based on pathological differentiation,they are classified into well-differentiated neuroendocrine tumor(NET)and poorly-differentiated neuroendocrine carcinoma(NEC).In 2025,significant progress was made in the treatment of advanced NET,with multiple phase Ⅲ clinical trial results published,particularly notable advances in the field of radionuclide therapy.Two studies of peptide receptor radionuclide therapy from China demonstrated the efficacy of this approach in Chinese NET patients.A Japanese study on everolimus combined with lanreotide as first-line therapy for gastro-entero-pancreatic NETs suggested improved efficacy with combination therapy.Although phase Ⅲ data remain lacking in 2025 for treating advanced NEC,several phase Ⅰ/Ⅱ trials of novel immunotherapies showed promising results.This article reviews and summarizes the advances in medical treatments for NENs during 2025.关键词
神经内分泌肿瘤/药物治疗/肽受体放射性核素治疗/靶向治疗/免疫治疗Key words
Neuroendocrine neoplasms/Medical treatment/Peptide receptor radionuclide therapy/Targeted therapy/Immunotherapy引用本文复制引用
陈洛海,陈洁..2025年度神经内分泌肿瘤药物治疗研究进展[J].肿瘤综合治疗电子杂志,2026,12(1):14-21,8.
